Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 102 articles: HTML format

Single Articles

July 2026
1. HASEGAWA N, Hoshiai S, Yamada T, Takahashi N, et al
   Balloon-occluded Alternative Infusion of Fragmented Gelatin Particles of TACE for Hepatocellular Carcinoma Refractory to Atezolizumab-Bevacizumab.
   Anticancer Res. 2026;46:3897-3906.
   PubMed     Abstract available
   
   
   
2. ONO A, Masuda T, Okabe H, Tomita M, et al
   Rapidly Progressive Multiple Hepatic Hemangiomas Mimicking Angiosarcoma: A Case Report With Surgical and Interventional Management.
   Anticancer Res. 2026;46:4161-4167.
   PubMed     Abstract available
   
   
   
3. NAKAMURA D, Motoyoshi Y, Nagaoka S, Komori A, et al
   Complementary Prognostic Value of ALBI Grade and Child-Pugh Classification in HCC Treated With SBRT.
   Anticancer Res. 2026;46:3955-3965.
   PubMed     Abstract available
   
   
   
4. KUWANO A, Yada M, Tanaka K, Hamamoto T, et al
   Pretreatment Tumor-infiltrating CD8(+) T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma.
   Anticancer Res. 2026;46:4077-4085.
   PubMed     Abstract available
   
   
   May 2026
5. TANAKA K, Kuwano A, Yada M, Suzuki H, et al
   Identification of Risk Factors for the Local Recurrence of Hepatocellular Carcinoma Post-radiofrequency Ablation.
   Anticancer Res. 2026;46:2609-2618.
   PubMed     Abstract available
   
   
   
6. AVSAR H, Eroglu I, Demirci A, Gonul II, et al
   Ovarian Metastasis from EBV-Associated Undifferentiated Nasopharyngeal Carcinoma: An Exceptionally Rare Occurrence.
   Anticancer Res. 2026;46:2937-2943.
   PubMed     Abstract available
   
   
   
7. LOU Y, Chen NI, Zheng J, Jiang X, et al
   IBP1 Represses the Migration and Invasion of Hepatocellular Carcinoma Cells by Inhibiting SOCE-dependent Formation of Neutrophil Extracellular Traps by Targeting the Akt Pathway.
   Anticancer Res. 2026;46:2509-2523.
   PubMed     Abstract available
   
   
   
8. MURANUSHI R, Yoshioka I, Kimura N, Fukasawa M, et al
   Diameter of IPDA Is Associated With Maintenance of Hepatic Arterial Blood Flow in DP-CAR.
   Anticancer Res. 2026;46:2671-2681.
   PubMed     Abstract available
   
   
   April 2026
9. ZHOU Y, Nakamura M, Makita K, Hiroshima Y, et al
   Clinical Outcomes of Proton Beam Therapy for Hepatocellular Carcinoma Adjacent to the Gastrointestinal Tract.
   Anticancer Res. 2026;46:2175-2185.
   PubMed     Abstract available
   
   
   
10. HOSHIAI S, Yamada T, Kobayashi M, Amano T, et al
    Balloon-occluded Infusion of Fragmented Gelatin Particles of Transarterial Embolization for Hypervascular Hepatic Metastases: A Prospective Trial.
    Anticancer Res. 2026;46:2053-2062.
    PubMed     Abstract available
    
    
    
11. SHIMOHIGASHI Y, Toya R, Kai Y, Doi Y, et al
    Whole-liver Palliative Radiotherapy Using SIB for Diffuse Liver Metastases: 3D-CRT versus (99m)Tc-GSA SPECT Image-guided VMAT.
    Anticancer Res. 2026;46:2277-2284.
    PubMed     Abstract available
    
    
    
12. KATAYAMA R, Aoki T, Tashiro Y, Hirai T, et al
    Relationship Between Histopathological Growth Patterns and Indocyanine Green Fluorescence in Colorectal Liver Metastases.
    Anticancer Res. 2026;46:2087-2093.
    PubMed     Abstract available
    
    
    March 2026
13. LIU Y, Cao J, Yu H, Sun Q, et al
    Dual Role of PSMB9 Linking Immune Activation and Tumor Adaptation in Hepatocellular Carcinoma With Therapeutic and Prognostic Implications.
    Anticancer Res. 2026;46:1389-1410.
    PubMed     Abstract available
    
    
    
14. MOHRI K, Nagai H, Mukozu T, Matsui T, et al
    Clinical Utility of Tremelimumab/Durvalumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: Serum Cytokine Profile Insights.
    Anticancer Res. 2026;46:1545-1556.
    PubMed     Abstract available
    
    
    
15. MUTO H, Kuzuya T, Tachi Y, Nagano Y, et al
    Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab-Bevacizumab.
    Anticancer Res. 2026;46:1609-1618.
    PubMed     Abstract available
    
    
    
16. TSUJI M, Kobayashi K, Kawakami K, Fukuda N, et al
    Real-world Analysis of Urinary Protein-to-Creatinine Ratio and Blood Pressure in Lenvatinib Therapy.
    Anticancer Res. 2026;46:1651-1659.
    PubMed     Abstract available
    
    
    
17. MAIMON O, Nisman B, Ben-David I, Kuznetz A, et al
    Autologous Tumor Vaccination in Melanoma and Colon Cancer Patients With Recurrent Liver Metastases: A Case Series.
    Anticancer Res. 2026;46:1569-1575.
    PubMed     Abstract available
    
    
    February 2026
18. MATSUI S, Kato Y, Ohgi K, Ashida R, et al
    Clinical Relevance of the CALLY Index in Prognostic Stratification of Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2026;46:963-974.
    PubMed     Abstract available
    
    
    January 2026
19. OKUYAMA S, Ueno M, Oi T, Nishikawa S, et al
    A Prospective Study of Olanzapine and Aprepitant for CINV in Cisplatin-HAIC for Hepatocellular Carcinoma (PROACT).
    Anticancer Res. 2026;46:395-405.
    PubMed     Abstract available
    
    
    December 2025
20. WU J, Fu X, Chang S, Su W, et al
    Homochlorcyclizine Dihydrochloride Inhibits Hepatocellular Carcinoma Progression and Cancer Stem Cell Properties.
    Anticancer Res. 2025;45:5465-5475.
    PubMed     Abstract available
    
    
    
21. KUWANO A, Tanaka K, Hamamoto T, Kurosaka K, et al
    Prior Radiotherapy Improves Progression-free Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Tremelimumab-Durvalumab.
    Anticancer Res. 2025;45:5697-5708.
    PubMed     Abstract available
    
    
    
22. HAYASHI K, Suzuki O, Ichise K, Uchida H, et al
    Carbon-ion Radiotherapy for Hepatocellular Cancer Arising in Transplanted Liver Tissue.
    Anticancer Res. 2025;45:5807-5812.
    PubMed     Abstract available
    
    
    
23. FURUKAWA K, Haruki K, Shirai Y, Onda S, et al
    Pulmonary Emphysema Assessed by the Goddard Score Predicts Outcomes After Hepatic Resection for Colorectal Liver Metastases.
    Anticancer Res. 2025;45:5765-5772.
    PubMed     Abstract available
    
    
    
24. TANIOKA N, Seo S, Kawanishi Y, Fujisawa K, et al
    Precise Anatomical Resection of the Left Lateral Section Using Extrahepatic Glissonean Approach and Fluorescence Guidance.
    Anticancer Res. 2025;45:5689-5695.
    PubMed     Abstract available
    
    
    November 2025
25. XUE X, Huang Q, Bai X, Yang J, et al
    Combination Strategy of Arsenic Trioxide and its Metabolite For Leukemia Treatment and Modulation of Endoplasmic Reticulum-mediated Hepatotoxicity.
    Anticancer Res. 2025;45:4941-4958.
    PubMed     Abstract available
    
    
    October 2025
26. TAKAHASHI H, Kojima D, Miyasaka Y, Wada H, et al
    Neoadjuvant Chemotherapy for Initially Resectable Metachronous Colorectal Cancer Liver Metastases Is Associated With Early Postoperative Relapse.
    Anticancer Res. 2025;45:4547-4564.
    PubMed     Abstract available
    
    
    
27. KITAOKA A, Oura K, Fujita K, Sasaki K, et al
    Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:4211-4229.
    PubMed     Abstract available
    
    
    
28. TAKEDA S, Namisaki T, Koizumi A, Takaya H, et al
    The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:4493-4507.
    PubMed     Abstract available
    
    
    
29. KARASHIMA R, Masuda T, Nagayama Y, Adachi Y, et al
    Hepatic Pseudolipoma Mimicking Fat-containing Malignant Liver Tumor: A Case of Migration from the Pelvic Cavity.
    Anticancer Res. 2025;45:4653-4658.
    PubMed     Abstract available
    
    
    
30. KUWANO A, Yada M, Tanaka K, Hamomoto T, et al
    Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study.
    Anticancer Res. 2025;45:4627-4636.
    PubMed     Abstract available
    
    
    September 2025
31. HO WH, Jhuang YC, Liang JA, Lin YC, et al
    Impact of Tumor Size on Patients With Hepatocellular Carcinoma Treated With Stereotactic Ablative Radiotherapy.
    Anticancer Res. 2025;45:3961-3970.
    PubMed     Abstract available
    
    
    
32. KOMORI H, Masuda T, Kurano R, Sugita H, et al
    A Rare Case of Fibrolamellar Hepatocellular Carcinoma in an Elderly Patient With Prior Hepatitis C Achieving Sustained Virologic Response.
    Anticancer Res. 2025;45:4047-4055.
    PubMed     Abstract available
    
    
    August 2025
33. SAKAI H, Goto Y, Fukutomi S, Arai S, et al
    Standardized Technique for Minimally Invasive Right Posterior Sectionectomy for Hepatocellular Carcinoma: A Propensity Score-matched Study.
    Anticancer Res. 2025;45:3497-3510.
    PubMed     Abstract available
    
    
    
34. FUKUTOMI S, Sakai H, Goto Y, Hashimoto K, et al
    Short- and Long-term Outcomes of Laparoscopic Versus Open Repeat Hepatectomy for Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:3523-3530.
    PubMed     Abstract available
    
    
    July 2025
35. SHIM HJ, Park MS, Bae WK, Cho SH, et al
    ITGAV Regulation of LGALS3BP-JUNB Axis Facilitates the Cell-to-Cell Adhesion and Invasiveness of Hepatic Cancer Cells.
    Anticancer Res. 2025;45:2997-3008.
    PubMed     Abstract available
    
    
    
36. MUTO-FUJITA E, Yamaoka B, Abe N, Fujiwara K, et al
    Ketone Bodies Inhibit Growth of Hepatoblastoma and Rhabdoid Tumor of the Kidney Cells.
    Anticancer Res. 2025;45:3089-3097.
    PubMed     Abstract available
    
    
    
37. LIN KH, Tsai CJ, Chen YT, Lin RF, et al
    Amentoflavone Enhances the Anti-tumor Activity of Regorafenib by Promoting Apoptosis and Inhibiting NF-kappaB-mediated Metastasis in Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:3045-3058.
    PubMed     Abstract available
    
    
    April 2025
38. KUWANO A, Yada M, Tanaka K, Takahira J, et al
    Mid-term Combination Immunotherapy and its Effect on the Albumin-Bilirubin Score in Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:1713-1721.
    PubMed     Abstract available
    
    
    
39. MASUDA T, Beppu T, Miyamoto H, Nagayama Y, et al
    A Huge Hepatocellular Carcinoma With Major Arteriovenous Shunt Successfully Treated With Chemoembolization Plus Lenvatinib Therapy Followed by Radiotherapy.
    Anticancer Res. 2025;45:1785-1792.
    PubMed     Abstract available
    
    
    
40. IZUTSU R, Osaki M, Seong H, Sato R, et al
    Hepatic Stellate Cells Activated by Cancer Cell-derived AMIGO2-containing Small Extracellular Vesicles Promote Cancer Cell Migration by Producing IL-8.
    Anticancer Res. 2025;45:1435-1446.
    PubMed     Abstract available
    
    
    
41. MASUDA T, Beppu T, Nagayama Y, Miyamoto H, et al
    Splenic Angiosarcoma and Numerous Liver Metastases Presenting the Kasabach-Merritt Phenomenon.
    Anticancer Res. 2025;45:1777-1784.
    PubMed     Abstract available
    
    
    March 2025
42. FUJISAWA T, Hojo H, Nakamura M, Makita K, et al
    Clinical Outcomes of Patients Receiving Stereotactic Body Radiotherapy Dose De-escalation for Hepatocellular Carcinoma at the Hepatic Hilum.
    Anticancer Res. 2025;45:1159-1169.
    PubMed     Abstract available
    
    
    
43. TANABE N, Saeki I, Yamaoka K, Kawaoka T, et al
    Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma.
    Anticancer Res. 2025;45:1117-1125.
    PubMed     Abstract available
    
    
    
44. WHI W, Lee H, Hong JY, Kang W, et al
    (18)F-Fluorocholine PET/CT as an Imaging Biomarker in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.
    Anticancer Res. 2025;45:1273-1280.
    PubMed     Abstract available
    
    
    
45. RYUNO Y, Abe T, Tsukahara K, Watanabe J, et al
    Stereotactic Body Radiotherapy Using CyberKnife for Metastatic Liver Tumors: A Single-center Retrospective Study.
    Anticancer Res. 2025;45:1127-1136.
    PubMed     Abstract available
    
    
    
46. WEISS TS, Buechler C
    Proprotein Convertase Subtilisin/Kexin Type 9 Induction in Hypercholesterinemic Patients With Primary and Metastatic Liver Tumors.
    Anticancer Res. 2025;45:1171-1180.
    PubMed     Abstract available
    
    
    February 2025
47. KAMIYA H, Imamura T, Ikoma H, Morimura R, et al
    Peak-postoperative Serum Transaminases Correlate With Post-hepatectomy Liver Failure and Inflow Occlusion After Laparoscopic Liver Resection.
    Anticancer Res. 2025;45:691-700.
    PubMed     Abstract available
    
    
    
48. DOKDUANG H, Jarernrat A, Titapun A, Sitthirak S, et al
    Characterization of Patient-derived Xenograft Models of Liver Fluke-associated Cholangiocarcinoma: From Establishment to Molecular Profiling.
    Anticancer Res. 2025;45:579-592.
    PubMed     Abstract available
    
    
    January 2025
49. KAWAMURA H, Imaizumi T, Miyakawa T, Nakao E, et al
    Development of a Prognostic Model for Stage IV Colorectal Cancer Using Metastatic Patterns.
    Anticancer Res. 2025;45:341-350.
    PubMed     Abstract available
    
    
    
50. KAWAMOTO M, Miyasaka Y, Kaida H, Watanabe M, et al
    Preoperative High FIB-4 Index and NFS Scores Predict a Reduced Incidence of Metachronous Liver Metastasis Following Pancreaticoduodenectomy.
    Anticancer Res. 2025;45:261-266.
    PubMed     Abstract available
    
    
    
51. ABE K, Fujioka S, Takano Y, Shirai Y, et al
    Lipoprotein(a) as a Predictor of Nonalcoholic Fatty Liver After Pancreatectomy.
    Anticancer Res. 2025;45:287-293.
    PubMed     Abstract available
    
    
    
52. ISHIHARA N, Komatsu S, Yano Y, Fujishima Y, et al
    Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:251-260.
    PubMed     Abstract available
    
    
    
53. PETRUCH N, Bolm L, Nebbia M, Arya S, et al
    How to Predict Recurrence After Resection of Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:189-199.
    PubMed     Abstract available
    
    
    December 2024
54. TATEISHI A, Okuma Y, Goto Y, Arakaki M, et al
    Key Therapeutic Agents for Thymic Carcinoma in Real-world Clinical Practice.
    Anticancer Res. 2024;44:5501-5513.
    PubMed     Abstract available
    
    
    
55. LEE HH, Oh S, Kang H, Cho H, et al
    Blocking CXCR3B Expression Increases Tumor Aggressiveness in Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:5293-5301.
    PubMed     Abstract available
    
    
    
56. FU CY, Liao PA, Lin TH, Hsu FT, et al
    Imipramine-mediated Suppression of EGFR Signaling Attenuates Invasive and Progressive Abilities of Hepatocellular Carcinoma Cells.
    Anticancer Res. 2024;44:5323-5335.
    PubMed     Abstract available
    
    
    November 2024
57. MOON SU, Shah M, Thao TT, Woo HG, et al
    Long Non-coding RNA TPRG1-AS1 Interacts With CLTC in Liver Cancer Cells.
    Anticancer Res. 2024;44:4813-4824.
    PubMed     Abstract available
    
    
    October 2024
58. MATSUBARA K, Kobayashi T, Tadokoro T, Namba Y, et al
    The Dominant Component and Clinicopathological Characteristics of Combined Hepatocellular-cholangiocarcinoma After Radical Resection.
    Anticancer Res. 2024;44:4551-4559.
    PubMed     Abstract available
    
    
    September 2024
59. HOSOKAWA A, Tamura H, Ichihara A, Imamura N, et al
    Pathological Complete Response to Liver Metastasis With Pembrolizumab in a Previously Treated Patient With Microsatellite Instability-high Colorectal Cancer.
    Anticancer Res. 2024;44:4119-4125.
    PubMed     Abstract available
    
    
    
60. FURUKAWA K, Tsunematsu M, Haruki K, Onda S, et al
    Postoperative Nutritional Assessment of Laparoscopic Versus Open Partial Hepatectomy.
    Anticancer Res. 2024;44:3931-3936.
    PubMed     Abstract available
    
    
    
61. MOHRI K, Nagai H, Matsuda T, Igarashi Y, et al
    Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab.
    Anticancer Res. 2024;44:3919-3929.
    PubMed     Abstract available
    
    
    
62. FRACCAROLI A, Barnikel M, Scheubeck G, Buchstab O, et al
    Stealthy Invader: Clinically Inapparent But Rapidly Progressive Multifocal Metastatic Melanoma Unveiled as Root Cause of Liver Failure.
    Anticancer Res. 2024;44:4127-4132.
    PubMed     Abstract available
    
    
    
63. YAMAMOTO T, Ito T, Mizuno K, Yokoyama S, et al
    Impact of BMI and Body Composition on First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:4101-4111.
    PubMed     Abstract available
    
    
    
64. SEO J, Park M, Cho S
    NSC-38270 Exhibits Anti-invasive and Pro-apoptotic Effects on Hepatocellular Carcinoma Huh7 Cells.
    Anticancer Res. 2024;44:3857-3866.
    PubMed     Abstract available
    
    
    
65. TAKEDA K, Kikuchi Y, Sawada YU, Kumamoto T, et al
    Simultaneously Detected Liver and Lung Metastases from Colorectal Carcinoma: A Potential Treatment Strategy.
    Anticancer Res. 2024;44:3945-3954.
    PubMed     Abstract available
    
    
    
66. TAMAKI N, Mori N, Takaki S, Tsuji K, et al
    Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:3913-3918.
    PubMed     Abstract available
    
    
    August 2024
67. SAKAI H, Goto Y, Fukutomi S, Arai S, et al
    Safety and Feasibility of Laparoscopic Anatomical Liver Resection for Hepatocellular Carcinoma: A Propensity Score-matched Study.
    Anticancer Res. 2024;44:3645-3653.
    PubMed     Abstract available
    
    
    
68. NAGATA T, Shakado S, Yamauchi E, Tokushige H, et al
    Tranilast Inhibits TRPV2 and Suppresses Fibrosis Progression and Weight Gain in a NASH Model Mouse.
    Anticancer Res. 2024;44:3593-3604.
    PubMed     Abstract available
    
    
    
69. GOTO Y, Niizeki T, Sakai H, Akashi M, et al
    A Multidisciplinary Therapeutic Approach Proposal for Huge Hepatocellular Carcinomas Exceeding 10 cm in Diameter.
    Anticancer Res. 2024;44:3629-3636.
    PubMed     Abstract available
    
    
    
70. HASHIMOTO K, Kanno H, Sakai H, Miyazaki D, et al
    Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score As a Predictor of Prognosis After Hepatectomy.
    Anticancer Res. 2024;44:3669-3678.
    PubMed     Abstract available
    
    
    
71. ARAI S, Sakai H, Akashi M, Goto Y, et al
    Clinicopathological Study of Resected and Recurrent Cases of Intrahepatic Intraductal Papillary Neoplasm of the Bile Duct.
    Anticancer Res. 2024;44:3623-3628.
    PubMed     Abstract available
    
    
    July 2024
72. KOMATSU S, Yano Y, Mimura T, Minami A, et al
    Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:3097-3103.
    PubMed     Abstract available
    
    
    
73. MIZUNO F, Imai N, Mizuno K, Yokoyama S, et al
    Clinical Outcomes of Use of the Porous Glass Membrane Pumping Emulsification Device During Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:3185-3191.
    PubMed     Abstract available
    
    
    June 2024
74. TOREN W, Sasor A, Ansari D, Andersson R, et al
    ARHGAP4 as a Prognostic Biomarker for Colon Liver Metastases After Surgical Resection.
    Anticancer Res. 2024;44:2597-2604.
    PubMed     Abstract available
    
    
    
75. IGARASHI Y, Haruki K, Furukawa K, Taniai T, et al
    Short-term Outcomes of Laparoscopic Versus Open Liver Resection in the Elderly: A Propensity Score-matched Analysis.
    Anticancer Res. 2024;44:2731-2736.
    PubMed     Abstract available
    
    
    
76. FUKUSHIMA NM, Adachi T, Tanaka T, Matsushima H, et al
    DCLK1 Expression and its Functional Significance in Intrahepatic Cholangiocarcinoma and Bil-IN Stage.
    Anticancer Res. 2024;44:2417-2424.
    PubMed     Abstract available
    
    
    May 2024
77. WAGNER D, Karitnig R, Wienerroither V, Hau HM, et al
    Sarcopenic Obesity Promotes Recurrence in Patients Undergoing Resection for Colorectal Liver Metastases (CRLM).
    Anticancer Res. 2024;44:2177-2183.
    PubMed     Abstract available
    
    
    
78. GON H, Komatsu S, Omiya S, Kido M, et al
    The Albumin-bilirubin Grade as Prognostic Indicator for Recurrent Hepatocellular Carcinoma Needing Repeat Liver Resection.
    Anticancer Res. 2024;44:2031-2038.
    PubMed     Abstract available
    
    
    
79. TSUNEMATSU M, Onda S, Shirai Y, Abe K, et al
    Strategies to Perform Emergency Laparoscopic Partial Liver Resection for Ruptured Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:2171-2176.
    PubMed     Abstract available
    
    
    
80. SEO SH, Yu JI, Park HC, Yoo GS, et al
    Proton Beam Radiotherapy as a Curative Alternative to Radiofrequency Ablation for Newly Diagnosed Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:2219-2230.
    PubMed     Abstract available
    
    
    
81. KOIZUMI A, Komatsu S, Omiya S, Yano Y, et al
    Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:2055-2061.
    PubMed     Abstract available
    
    
    
82. IKUTA S, Aihara T, Kasai M, Nakajima T, et al
    Long-term Outcomes of Hepatic Resection Combined With Intraoperative Ablation Versus Hepatic Resection Alone for Multinodular Hepatocellular Carcinoma: Insights from a Single-center Study.
    Anticancer Res. 2024;44:2133-2140.
    PubMed     Abstract available
    
    
    
83. JUNG JY, Koh SA, Lee KH
    Cold-shock Domain Protein A (CSDA) Influences Hepatocyte Growth Factor-medicated Cell Proliferation and Metastasis in Gastric Cancer Cells.
    Anticancer Res. 2024;44:1973-1981.
    PubMed     Abstract available
    
    
    April 2024
84. OKUNO M, Hatano E, Tada M, Nishimura T, et al
    Surgical Intervention After Lenvatinib Treatment in Patients With Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:1727-1737.
    PubMed     Abstract available
    
    
    
85. BEPPU T, Yamamura K, Masuda T, Miyamoto H, et al
    High-risk Patients With Colorectal Liver Metastases Assessed by the Beppu Score Can Have Excellent Survival Through Multidisciplinary Treatment Including Local Ablation.
    Anticancer Res. 2024;44:1533-1539.
    PubMed     Abstract available
    
    
    February 2024
86. ACS M, Herold Z, Neumann L, Slowik P, et al
    Surgical Treatment and Outcome of Ovarian Cancer Patients With Liver Metastases: Experience of a Tertiary Hepatic and Peritoneal Surface Malignancy Center.
    Anticancer Res. 2024;44:731-741.
    PubMed     Abstract available
    
    
    
87. KIM Y, Ajiki T, Ueda Y, Yoshida Y, et al
    Reappraisal of a Renovated Cell-free and Concentrated Ascites Reinfusion Therapy for Malignant Ascites.
    Anticancer Res. 2024;44:613-619.
    PubMed     Abstract available
    
    
    
88. IMAOKA K, Ohira M, Shimomura M, Hattori M, et al
    Effect of Abdominal Aortic Calcification on Recurrence Following Initial Hepatectomy for Colorectal Liver Metastases.
    Anticancer Res. 2024;44:649-658.
    PubMed     Abstract available
    
    
    January 2024
89. ISHIKAWA T, Yamazaki S, Sato R, Jimbo R, et al
    Efficacy of Adding Locoregional Therapy in Non-Complete Remission Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Preliminary Study.
    Anticancer Res. 2024;44:361-368.
    PubMed     Abstract available
    
    
    
90. CHIBA N, Abe Y, Ando A, Nakagawa M, et al
    A Standardized Interrupted Parachute Suture Technique in Hepaticojejunostomy for Patients With Perihilar Cholangiocarcinoma.
    Anticancer Res. 2024;44:167-171.
    PubMed     Abstract available
    
    
    December 2023
91. TOMIOKA K, Aoki T, Tashiro Y, Kusano T, et al
    Laparoscopic Anatomical Liver Resection Using Liver Mapping of Incidental Indocyanine Green Fluorescence due to Cholestasis.
    Anticancer Res. 2023;43:5583-5588.
    PubMed     Abstract available
    
    
    
92. ZHANG XW, Mohr J, Halama N, Koschny R, et al
    Analysis of an Unselected Patient Cohort With Advanced Colorectal Carcinoma from a Maximum Care Center.
    Anticancer Res. 2023;43:5589-5596.
    PubMed     Abstract available
    
    
    November 2023
93. SHIOZAKI A, Kurashima K, Kudou M, Shimizu H, et al
    Cancer Stem Cells of Hepatocellular Carcinoma Are Suppressed by the Voltage-gated Calcium Channel Inhibitor Amlodipine.
    Anticancer Res. 2023;43:4855-4864.
    PubMed     Abstract available
    
    
    
94. SANO A, Sohda M, Hosoi N, Tateno K, et al
    Importance of Progression-free Survival in Second-line Chemotherapy in Patients With Advanced or Recurrent Gastric Cancer.
    Anticancer Res. 2023;43:5205-5213.
    PubMed     Abstract available
    
    
    
95. OSHITA KO, Kobayashi T, Tadokoro T, Namba Y, et al
    Outcomes and Prognostic Analysis of Surgical Resection for Oligometastasis from Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:5189-5196.
    PubMed     Abstract available
    
    
    October 2023
96. KOBAYASHI K, Nagai H, Matsui T, Matsuda T, et al
    Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:4601-4609.
    PubMed     Abstract available
    
    
    
97. MUTO H, Kuzuya T, Kawabe N, Ohno E, et al
    Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:4673-4682.
    PubMed     Abstract available
    
    
    
98. GARRETT C, Cristaudo A, Barat S, Morris DL, et al
    Increased Incidence of Liver Metastases in Colorectal Versus Appendiceal Adenocarcinoma Peritonectomy Patients Despite Equivocal Survival.
    Anticancer Res. 2023;43:4657-4662.
    PubMed     Abstract available
    
    
    
99. YANG JD, Yueh PF, Liao TL, Chen YT, et al
    Unlocking Synergistic Potential: Enhancing Regorafenib Efficacy in Hepatocellular Carcinoma Through Combination Therapy With 18beta-Glycyrrhetinic Acid.
    Anticancer Res. 2023;43:4403-4412.
    PubMed     Abstract available
    
    
    
100. WANG CC, Fan WL, Liu TT, Pang ST, et al
     Impact of Genomic Alterations on the Clinical Outcome of Patients With Hepatitis B-related Hepatocellular Carcinoma Receiving Curative Surgery: A Retrospective Cohort Study.
     Anticancer Res. 2023;43:4709-4722.
     PubMed     Abstract available
     
     
     
101. LEE YJ, Kim KC, Lee JM, Lim JM, et al
     Development of Polyethylene Glycol-based Hydrogels Optimized for In Vitro 3D Culture of HepG2 Hepatocarcinoma Cells.
     Anticancer Res. 2023;43:4373-4377.
     PubMed     Abstract available
     
     
     
102. YAMAMURA K, Beppu T, Miyata T, Mima K, et al
     Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy.
     Anticancer Res. 2023;43:4285-4293.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum